Effect of Moderate and High-Dose Simvastatin on Asymmetric Dimethylarginine-Homocysteine Metabolic Pathways in Patients with Newly Detected Severe Hypercholesterolemia

Cardiovascular Therapeutics

Volumn 29, Issue 5, 2011, Pages 340-348

  Vladimirova Kitova, Lyudmila G ^a   Deneva, Tania I ^a   Marinov, B ^a  

^a MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

Author keywords

Asymmetric dimethylarginine; Endothelial dysfunction; Hypercholesterolemia; Low density lipoprotein cholesterol; Nitric oxide; Nitric oxide synthase; Simvastatin; Statins; Target; Total homocysteine

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; SIMVASTATIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ARGININE; BIOLOGICAL MARKERS; BULGARIA; CHOLESTEROL, LDL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053155357     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00149.x     Document Type: Article

References (44)

1. Greenland P, Abrams J, Aurigemma GP, et al. Prevention Conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: Noninvasive tests of atherosclerotic burden: Writing Group III. Circulation 2000;101:e16-e22.
2. Favre A, Monpere C, Voyer C, Mirguet C, Quilliet-Thebaud N, Vernochet P, Brochier M. How to improve primary prevention in asymptomatic high risk subjects. Eur Heart J 2004;6(Suppl J):J59-J63.
3. Schuster H. Under-treated high risk patients: Identifying patients in high-risk subgroup and treating them to LDL targets Eur Heart J 2005;7(Suppl A):20-28.
4. Wolfrum S, Liao J. The pleiotropic effects of statins: Relevance to their salutary effects. In: Mehta JL, editor. Statins: Understanding clinical use. Pennsylvania: Saunders, 2004;163-187.
5. Davignon J. The cardioprotective effects of statins. Curr Atheroscler Rep 2004;6:27-35.
6. Laufs U, La F, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135.
7. Böger RH, Vallance P, Cooke JP. Asymmetric dimethylarginine (ADMA): A key regulator of nitric oxide synthase. Atherosclerosis 2003;4(Suppl 4):1-3.
8. Böger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 2003;41:1467-1472.
9. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:998-1005.
10. Böger RH, Cooke JP, Vallance P. ADMA: An emerging cardiovascular risk factor. Vasc Med 2005;10:S1-S2.
11. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-3095.
12. Böger RH. Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond. Ann Med 2006;38:126-136.
13. Böger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells. Circ Res 2000;87:99-105.
14. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction. It's role in hypercholesterolemia. Circulation 1998;98:1842-1847.
15. Jang JJ, Ho HKV, Kwan HH, Fajardo LF, Cooke JP. Angiogenesis is impaired by hypercholesterolemia. Role of asymmetric dimethylarginine. Circulation 2000;102: 1414-1419.
16. Achan V, Ho HK, Heeschen C, et al. ADMA regulates angiogenesis: Genetic and metabolic evidence. Vasc Med 2005;10:7-14.
17. Cooke JP. ADMA: Its role in vascular disease. Vasc Med 2005;10:S11-S17.
18. Ardigo D, Stuehlinger M, Franzini L, et al. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Invest 2007;37:263-269.
19. Juonala M, Viikari J, Alfthan G, et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 2007;116:1367-1373.
20. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I. Increased levels of asymmetric dimethylarginine in population at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003;166:279-284.
21. Janatuinen T, Laakso J, Laaksonen R, Nuutila P, Lehtimaki T, Raitakari OT, Knuuti J. Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vasc Med 2003;8:185-189.
22. Jiang J, Jiang D, Tang Y, Li N, Deng H, Li Y. Effect of simvastatin on endothelium-dependent vasorelaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol Sin 2004;25:893-901.
23. Periera EC, Bertolami MC, Faludi AA, Salem M, Bersch D, Abdalla D. Effects of Simvastatin and L-Arginine on Vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects. Free Radic Res 2003;37:529-536.
24. Päivä H, Laakso J, Lehtimäki T, Isomustajärvi M, Ruoko I, Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 2003;41:219-222.
25. Valkonen VP, Laakso J, Päivä H, et al. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events: Does statin treatment influence plasma ADMA levels? Atherosclerosis 2003;4(Suppl 4):19-22.
26. Shinohara KB, Shoji T, Kimoto E, et al. Effect of Atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2005;12:205-210.
27. Bolayirli IM, Aslan M, Balci H, Altug T, Hacibekiroglu M, Seven A. Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci 2007;81:121-127.
28. Sasaki S, Kuwahara N, Kunitomo K, et al. Effects of Atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution and remnants lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 2002;89:386-389.
29. Lu TM, Ding YA, Leu HB. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004;94:157-161.
30. Oguz A, Uzunlulu M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. Int Heart J 2008;49:303-311.
31. Böger RH. Asymmetric dimethylarginine (ADMA) modulates endothelial function-therapeutic implications. Vasc Med 2003;8:149-151.
32. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolemia: Implications for clinical management. Atherosclerosis 1999;142:105-112.
33. Vladimirova-Kitova LG, Deneva TI, Angelova E, Bichev AN, Nikolov FP. Role of some biomarkers of atherogenic risk in the screening for molecular defects in the low density lipoprotein receptor in severe hypercholesterolemia. Folia Med 2008;50:14-22.
34. Vladimirova-Kitova LG, Deneva T, Angelova E, Nikolov F, Marinov B, Mateva N. Relationship of asymmetric dimethylarginine with flow-mediated dilation in subjects with newly detected severe hypercholesterolemia. Clin Physiol Funct Imaging 2008;28:417-425.
35. th Inter-national symposium on ADMA; 2008 28-29; Bremenz, Lake Constance, Austria
36. Lüftjohann D, Sigit JI, Locatelli S, Bergmann K. High-dose simvastatin (80 mg/day) decreases plasma concentrations of total homocysteine in patients with hypercholesterolemia. Atherosclerosis 2001;155:265-266.
37. Jankowski P, Kawecka-Jaszcz K. Lipid-lowering drugs and homocysteine a comparison between statins and other lipid-lowering drugs [letter]. Atherosclerosis 2004;172:191-194.
38. Miltiadous G, Papakostas J. Letter to the editor: Statins and homocysteine. Atherosclerosis 2003;166:199-200.
39. Böger GI, Rudolf TK, Renke M, et al. Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilatation by Simvastatin. J Am Coll Cardiol 2007;49:2274-2282.
40. Law M, Rudnicka AR. Statin safety: A systematic review. Am J Cardiol 2006;97:52C-60C.
41. Jacobson TA. Statin safety: Lessons from new drug applications for marketed statins. Am J Cardiol 2006;97:44C-51C.
42. De Lemos J, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative Simvastatin strategy in patients with acute coronary syndromes. JAMA 2004;292:1307-1316.
43. Link E, Parish S, Armitage J, et al. SEARCH Collaborative Group, "SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008;359:856-858.
44. Landmesser ULF, Hornig B, Drexler H. Endothelial dysfunction in hypercholesterolemia: Mechanism, pathophysiological importance and therapeutic interventions. Semin Thromb Hemost 2000;26:529-537.